New pill targets root cause of deadly lung pressure disease

This study is testing an oral compound called 2-HOBA to see if it can improve heart function and slow disease progression in people with pulmonary arterial hypertension (PAH). Researchers will enroll 12 adults with PAH to assess the drug's safety and its effects on exercise capacity, quality of life, and specific blood markers. The goal is to see if 2-HOBA, which works differently than current vasodilator treatments, can address the underlying metabolic problems thought to drive the disease.